



Advanced Molecular Diagnostic Systems

1 Dalmore Drive,  
Scoresby,  
Victoria 3179  
AUSTRALIA

T: +61 (0)3 9763-1287

F: +61 (0)3 9763-2817

[www.generabiosystems.com](http://www.generabiosystems.com)

**Monday 18 August 2014**

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)  
STRATEGIC COMMERCIAL ALLIANCE UPDATE**

Genera Biosystems Limited (**'Genera'**) is pleased to provide an update in relation to the status of a Strategic Commercial Alliance Agreement (**'SCAA'**) that it is currently finalising with a highly complementary international molecular diagnostics company.

Genera's and its partner IncellDx, Inc. (**'IncellDx'**), a US based molecular diagnostics company, have been in commercial discussions since early 2014 regarding the optimal approach to best leverage the sound strategic fit which exists between the companies.

Genera's Executive Chairman Lou Panaccio stated, "The strategic fit between Genera and IncellDx is compelling, not only in being able to offer a comprehensive HPV testing regime to rival that of Roche Diagnostics, but also in the ability to offer a broad menu of high-value MDx tests that may also leverage similar flow cytometry based instrumentation platforms. Achieving commercial alignment between our combined platform technologies and high-value MDx tests may provide material benefits for both companies, pathology customers, clinicians and their patients."

"Genera is fortunate to employ an expert team for the development of high-value MDx and our capabilities can be leveraged strongly with IncellDx's own development pipeline, its pathology customers as well as our own. IncellDx itself has assembled an exceptional high-calibre team both on the commercial and development front who have unequivocally demonstrated their ability to develop and commercialise world-leading MDx and we look forward to a long and rewarding relationship for all stakeholders under our proposed SCAA."

The terms of the SCAA are currently being finalised and documentation is being reviewed by legal counsel. Genera hopes to be in a position to announce more specific details pertaining to the SCAA by the close of business this week.

Genera looks forward to presenting to the market the merits of the proposed SCAA and the capabilities of IncellDx in coming weeks with a comprehensive Corporate Presentation to follow.

For personal use only



Advanced Molecular Diagnostic Systems

---

For further information please contact:

Mr Lou Panaccio  
Executive Chairman  
Genera Biosystems Limited  
Telephone: +61 (0)3 9763 1287  
[www.generabiosystems.com.au](http://www.generabiosystems.com.au)

**About Genera Biosystems:** Genera Biosystems Limited (“GBI”) is an Australian Stock Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests. GBI has successfully developed two products to date, PapType™ and RTI-Plex™, with several additional products in the company’s development pipeline. Genera manufactures these products in its Therapeutics Goods Administration (TGA) certified manufacturing facility in Scoresby, Victoria, Australia.

**About IncellDx:** IncellDx, Inc. (“IncellDx”) is committed to bringing personalized medicine to infectious disease testing through innovative molecular diagnostic products revolutionizing healthcare one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, IncellDx focuses on critical life threatening diseases such as HIV/AIDs, HPV/Cervical Cancer, Hepatitis, organ transplant infections, breast cancer and ovarian cancer. The company is privately held and located in Menlo Park, California.

IncellDx’s technology combines Simultaneous Ultrasensitive Signal-amplified Hybridization *In Situ* (SUSHI) with a novel, cell-based instrument capable of quantifying molecular biomarkers inside intact cells. This allows protein and gene expression to be measured by distinct cell type which aids both diagnosis and disease localization. The technology is ultra-fast, inexpensive, highly reproducible, and able to perform complex molecular testing without DNA extraction or amplification.

For personal use only